JAMA Oncology Author Interviews

JAMA Oncology Author Interviews

Por: JAMA Network
Interviews with authors of articles from JAMA Oncology. JAMA Oncology is the definitive journal for scientists, clinicians, and trainees in the field of oncology worldwide. Our original, innovative, and timely scientific and educational content provides a deeper understanding of cancer pathogenesis and recent treatment advances for our readers. JAMA Oncology aims to effectively convey the findings of important clinical research, major scientific breakthroughs, actionable discoveries, and state-of-the-art treatment pathways to the oncology community. Our goal is that successful communication of new knowledge will ultimately translate to clinical benefit for people living with and surviving cancer.
128 episodios disponibles

Latest episodes of the podcast JAMA Oncology Author Interviews

Mostrando página 3 de 7

Guideline-Concordant Surgery and Adjuvant Chemotherapy Among Patients With Early-Stage Lung Cancer 17/03/2022
Racial Disparity in Survival Outcomes for Early Hormone Receptor–Positive Breast Cancer 17/02/2022
Early Readout on Overall Survival of Patients With Melanoma Treated With Immunotherapy 20/01/2022
Atezolizumab Plus Bevacizumab vs Sunitinib in Patients With Previously Untreated Metastatic Renal Cell Carcinoma 23/12/2021
Chemoradiotherapy Plus Induction or Consolidation Chemotherapy for Locally Advanced Rectal Cancer 18/11/2021
Clinical Outcomes and Toxic Effects of Single-Agent ICI Treatment Among Geriatric Patients With Cancer 04/11/2021
Assessment of Residual Cancer Burden and Event-Free Survival in Neoadjuvant Treatment for High-Risk Breast Cancer 16/09/2021
Hypofractionated Image-Guided vs Conventional Radiotherapy for Patients With NSCLC 12/08/2021
Neuronal Autoantibodies and Cognitive Impairment in Patients With Lung Cancer 01/07/2021
Trastuzumab, Pertuzumab, and Docetaxel vs Trastuzumab Emtansine in ERBB2-Positive Breast Cancer 24/06/2021
Efficacy and Safety of Stereotactic Radiosurgery for Brainstem Metastases 13/05/2021
Association Between KRAS Variant Status and Outcomes With First-line Immune Checkpoint–Based Therapy in Patients With Advanced NSCLC 15/04/2021
Chronic Toxic Effects Following Adjuvant Anti–PD-1 Therapy for High-Risk Resected Melanoma 25/03/2021
Anti–PD-1 Immunotherapy in Microsatellite-Stable Tumors With 10 or More Mutations per Megabase 18/02/2021
Virtual Care Across a Tertiary Cancer Center During COVID-19 07/01/2021
Osteonecrosis of the Jaw in Patients Receiving Zoledronic Acid for Bone Metastases 17/12/2020
Discontinuation of Tyrosine Kinase Inhibitors for Patients With Chronic Myeloid Leukemia 12/11/2020
Association of Measurable Residual Disease With Survival in Patients With Acute Myeloid Leukemia 08/10/2020
Survival and Adjuvant Chemotherapy in Early-Stage NSCLC With vs Without Clinicopathologic Features 17/09/2020
Tailoring Intensity of Surveillance for Prostate Cancer Based on Prediction of Risk Stability 27/08/2020
« Primera ‹ Anterior 1 2 3 4 5 ... 7 Siguiente › Última »
© 2003-2025 ZARZA | AHEAD OF OUR TIME
privacy policy
In God we trust In God we trust
PreSales Questions? Click Here
or call our toll-free line at +1-888-5002068 Miami, Florida, USA